ECSP034616A - NEW DERIVATIVES OF PIRAZOLOPIRIDINA SUBSTITUTED WITH PIRIDINE - Google Patents

NEW DERIVATIVES OF PIRAZOLOPIRIDINA SUBSTITUTED WITH PIRIDINE

Info

Publication number
ECSP034616A
ECSP034616A EC2003004616A ECSP034616A ECSP034616A EC SP034616 A ECSP034616 A EC SP034616A EC 2003004616 A EC2003004616 A EC 2003004616A EC SP034616 A ECSP034616 A EC SP034616A EC SP034616 A ECSP034616 A EC SP034616A
Authority
EC
Ecuador
Prior art keywords
pirazolopiridina
piridine
substituted
new derivatives
designates
Prior art date
Application number
EC2003004616A
Other languages
Spanish (es)
Inventor
Johannes Peter Stasch
Stefan Weigand
Elisabeth Perzborn
Elke Stahl
Alexander Straub
Dieter Lang
Klaus Dembowsky
Achim Feurer
Alija Cristina Alonso
Dietmar Flubacher
Frank Wunder
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ECSP034616A publication Critical patent/ECSP034616A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la que R1 designa 4-piridina o 3 piridinilo R2 designa H. NH2 o halógeno, así como sales isomeros e hidratos de los mismos como estimulantes de la guanilatociclasa soluble y para el uso como agentes para el tratamiento de enfermedades cardiocirculatorias, hipertonia, trastornos tromboembolicos e isquemias disfunción sexual o inflamaciones así como para el tratamiento de enfermedades del sistema nervioso central.In which R1 designates 4-pyridine or 3 pyridinyl R2 designates H. NH2 or halogen, as well as isomeric salts and hydrates thereof as stimulants of soluble guanylate cyclase and for use as agents for the treatment of cardiocirculatory diseases, hypertonia, disorders thromboembolic and ischemia sexual dysfunction or inflammation as well as for the treatment of diseases of the central nervous system.

EC2003004616A 2000-11-22 2003-05-21 NEW DERIVATIVES OF PIRAZOLOPIRIDINA SUBSTITUTED WITH PIRIDINE ECSP034616A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10057753 2000-11-22

Publications (1)

Publication Number Publication Date
ECSP034616A true ECSP034616A (en) 2003-06-25

Family

ID=7664122

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004616A ECSP034616A (en) 2000-11-22 2003-05-21 NEW DERIVATIVES OF PIRAZOLOPIRIDINA SUBSTITUTED WITH PIRIDINE

Country Status (12)

Country Link
KR (1) KR20030065519A (en)
DE (2) DE10131987A1 (en)
DO (1) DOP2001000291A (en)
EC (1) ECSP034616A (en)
GT (1) GT200100235A (en)
HN (1) HN2001000261A (en)
MY (1) MY127212A (en)
PE (1) PE20020581A1 (en)
RU (1) RU2003118584A (en)
SV (1) SV2003000743A (en)
UA (1) UA74404C2 (en)
ZA (1) ZA200303887B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102485724B (en) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 Substituted thiophene base pyrazolo-pyridines and medicinal use thereof
ES2603028T3 (en) 2011-11-25 2017-02-23 Adverio Pharma Gmbh Procedure for the preparation of (Z) -alpha-fluoro-beta-amino-acrylaldehydes
EP3525779B1 (en) * 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Combination containing the sgc stimulator vericuguat and the mineralcorticoid receptor antagonist finerenone

Also Published As

Publication number Publication date
UA74404C2 (en) 2005-12-15
MY127212A (en) 2006-11-30
RU2003118584A (en) 2004-12-20
PE20020581A1 (en) 2002-07-13
GT200100235A (en) 2002-06-25
KR20030065519A (en) 2003-08-06
DE10131987A1 (en) 2002-05-23
DOP2001000291A (en) 2002-12-15
HN2001000261A (en) 2002-01-30
ZA200303887B (en) 2004-06-21
SV2003000743A (en) 2003-01-13
DE50106655D1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
AR031176A1 (en) NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
ECSP045081A (en) DERIVATIVES OF 1,8-NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
PA8597301A1 (en) DERIVATIVES OF IMIDAZOL-4-IL-ETINIL-PIRIDINA
PA8442201A1 (en) 6-PHENYLPIRIDYL-2-AMINE DERIVATIVES
SV2002000197A (en) NEW DERIVATIVES OF USEFUL BIARILETER AS INHIBITORS OF THE RECOVERY OF MONOAMINES REF. PC10602 / 20073 / BB
EA200300717A1 (en) Heterocyclylindazole and azazin-dazole compounds as 5-hydroxytriptamine-6-ligands
DK1578740T3 (en) 1,2,4-triaminobenzene derivatives suitable for the treatment of central nervous system disorders
UY27055A1 (en) GLUCOQUINASA FUSIONED HETEROAROMATIC ACTIVATORS
ES2147759T3 (en) NON-AROMATIC HETERO CYCLES SUBSTITUTED WITH AMINOMETHYLENE AND USE AS ANTAGONISTS OF THE SUBSTANCE P.
CL2004000655A1 (en) COMPOUNDS DERIVED FROM PIPERIDIN-2-ONA 1,6-DISUSTITUTED, ITS SALTS, PHARMACEUTICAL COMPOSITION, AGONISTS OF THE EP4 RECEIVER; USE OF COMPOUNDS TO TREAT OCULAR HYPERTENSION, GLAUCOMA.
EA200200647A1 (en) Β2-adrenergic receptor agonists
ECSP067116A (en) ANTIGONISTS OF THE CHEMIOATRAYING CITOCINE RECEIVER 2 OF QUATERNAL SALES
ES2154741T3 (en) USE OF CD23 UNION AGENTS IN THE TREATMENT OF AUTOIMMUNE DISEASES.
ES2156287T3 (en) DERIVATIVES OF DIFENILMETILEN PIPERIDINA.
ATE296809T1 (en) 3,4-DIHYDRO-(1H)CHINAZOLINE-2-ONE COMPOUNDS AS CSBP/P38 KINASE INHIBITORS
IT1282673B1 (en) CAMPTOTECIN DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS
ATE302776T1 (en) CONDENSED PYRIDOINDOLE DERIVATIVES
ECSP034616A (en) NEW DERIVATIVES OF PIRAZOLOPIRIDINA SUBSTITUTED WITH PIRIDINE
ATE281439T1 (en) 3,4-DIHYDRO-(1H)CHINAZOLINE-2-ONE COMPOUNDS AS CSBP/P38 KINASE INHIBITORS
AR028772A1 (en) 5-AMINOALQUIL-PIRAZOL [4,3-D] PYRIMIDINS
UY27998A1 (en) HETEROCYCLIC REPLACED SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF CHICHOPHRENIA
ES2196069T3 (en) MORFINOID DERIVATIVES CONDENSED WITH HETEROCICLES.
AR044055A1 (en) RISPERIDONE MONOHIDROCLORIDE
ECSP034532A (en) DERIVATIVES OF 1-AMINOBUTAN-3-OL REPLACED
AR035600A1 (en) USE OF SELECTIVE AGONISTS OF DOPAMINE D4 RECEPTOR IN THE MANUFACTURE OF MEDICINES TO TREAT SEXUAL DYSFUNCTION